Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: J Urol. 2016 Sep 14;197(3 Pt 1):632–639. doi: 10.1016/j.juro.2016.09.070

Table 3.

Univariate analysis of baseline clinical and histopathologic variables.

Rate of Upgrading per year of follow-up (95% CI) HR (95% CI) p
Gleason score
 3+3 0.06 (0.03–0.09)
 3+4 0.23 (0.14–0.38) 4.65 (2.32–9.34) < 0.01

PSA
 <10 ng/mL 0.08 (0.06–0.12)
 ≥10 ng/mL 0.15 (0.06–0.41) 1.97 (0.69–5.64) NS

PSA % free
 >10 % 0.06 (0.04–0.10)
 ≤10% 0.22 (0.13–0.39) 3.75 (1.85–7.60) < 0.01

PSA density
 < 0.15 ng/mL/cm3 0.06 (0.04–0.10)
 ≥ 0.15 ng/mL/cm3 0.20 (0.12–0.35) 3.43 (1.68–7.05) < 0.01

MRI grade
 < 3 (referent) 0.08 (0.03–0.17)
 3, 4, or 5 0.09 (0.06–0.13) 1.23 (0.51–2.98) NS
 5 0.35 (0.13–0.94) 5.16 (1.79–14.87) < 0.01

Maximum cancer core length
 <4 mm 0.08 (0.05–0.12)
 ≥4 mm 0.12 (0.06–0.24) 1.53 (0.71–3.30) NS

Maximum % tumor involvement in any core
 < 60% 0.09 (0.06–0.13)
 ≥60% 0.05 (0.01–0.34) 1.99 (0.27–14.59) NS

Number of positive cores
 ≤ 3 0.08 (0.06–0.11)
 > 3 0.17 (0.06–0.44) 2.26 (0.78–6.54) NS